Does a negative blood PCR rule out neuroborreliosis?

Neuroborreliosis is a tissue/CNS-focused manifestation of Lyme disease, so peripheral-blood molecular testing is poorly suited to rule it out. This is particularly relevant when a compatible neurological syndrome persists despite a negative blood PCR.

Clinical evidence

• A negative peripheral-blood Borrelia PCR does not reliably exclude neuroborreliosis. In a cohort of 48 patients with a working clinical diagnosis, blood PCR was positive in only 7 (14.6%); reviewed European studies reported sensitivities of 13% and 28%.
• In a prospective paired blood/CSF study, Borrelia DNA was found in only 16/135 blood samples (11.9%), with simultaneous blood and CSF positivity in only three patients. Thus, most clinically evaluated cases had no detectable DNA in the sampled blood.
• PCR is therefore not a useful stand-alone rule-out test. Its performance also varies with sampling timing, disease stage, assay target, specimen handling, prior antibiotics, and infecting Borrelia species.

Mechanistic and diagnostic implications

• PCR requires adequate target DNA within the specific blood volume collected. Low organism burden or transient spirochetemia can make a single blood sample negative even when infection involves other compartments.
• For suspected CNS neuroborreliosis, diagnostic assessment should integrate the neurological presentation with CSF findings and paired CSF/serum testing for a validated Borrelia-specific antibody index. An elevated index is highly specific for CNS neuroborreliosis.
• Even CSF PCR has limited acute sensitivity (typically 10–30%); a negative CSF PCR likewise does not exclude the diagnosis.

Bottom line

• A negative blood PCR provides insufficient reassurance to rule out neuroborreliosis. Low or transient circulating Borrelia DNA is a plausible explanation, but this principle should not be automatically generalized to every tissue-localized infection; testing strategy must be pathogen- and site-specific.